Financial Performance Highlights
Q2 FY27 Results (Quarter Ending September 30, 2026):
- Revenue: INR 507 crores (22% decline YoY)
- Cost of Goods Sold: INR 34 crores (approximately 7% of revenue)
- Employee Expenses: INR 321 crores
- Other Expenses: INR 105 crores (23% decline YoY)
- EBITDA: INR 46 crores
- Depreciation: INR 90 crores
- Finance Cost: INR 40 crores
H1 FY27 Results (Half Year Ending September 30, 2026):
- EBITDA: INR 106 crores
- Depreciation: INR 181 crores
Segment-wise Performance:
CDMO Business:
- Q2 Revenue: INR 388 crores (vs. INR 509 crores YoY)
- H1 Revenue: INR 929 crores (vs. INR 1,120 crores YoY)
- Q2 Margin: 12.3% (vs. 25% YoY)
- H1 Margin: 8.7% (vs. 21% YoY)
Marketable Molecules Segment:
- Q2 Revenue: INR 118 crores (vs. INR 143 crores YoY)
- H1 Revenue: INR 256 crores (vs. INR 240 crores YoY)
Operational and Strategic Updates
Market Conditions and Business Development:
- Market trends remain challenging but showing slight upward trend in early-phase projects
- Customers awaiting funding for early-phase programs
- Potential shift of venture capital from AI to pharmaceutical industry expected
- Company participated in multiple exhibitions (CPHI Milan, Festival of Biologics, BioJapan)
- Acquired significant projects in early clinical phase and clinical Phase II
Integration and Technology Transfers:
- Close interaction between Carbogen Amcis and Dishman India intensively promoted
- Multiple processes being transferred from Carbogen to Dishman India
- Two major technology transfers underway:
- First transfer: American company legacy product, on schedule for completion by end of FY27
- Second transfer: Expected to cover two additional pipeline products in upcoming year
- Combined annual revenue potential: CHF 25-30 million
- 9 senior employees from Carbogen Amcis Europe visiting India sites over four weeks
Facility and Infrastructure Updates:
- DCAL sites in Bavla and Naroda experiencing significant increase in audits and customer visits
- Received regulatory approvals including FDA and government NDA
- EDQM certificate of suitability granted
- New U.S. Drug Master File and letter of authorization submitted
- Largest BWT Switzerland purifying water plants in India completed at Bavla
- State-of-the-art infrastructure with largest distribution network and user points
Specific Project Highlights:
- Japanese innovator molecule co-investment expansion project on track
- Expected to go live in next financial year
- Revenue potential: CHF 15-20 million annually
- Naroda facility supported launch of macrocyclic peptide in U.S. market
- First commercial contract secured after July 2026 market approval
- Semiconductor project: Customer requested quotation for initial volume of several 100 metric tons
- Soft gel drug product operations experiencing significant business interest
Sales and Market Expansion:
- Increasing commercial team with focus on U.S. markets
- South American market expansion showing successes with new customers and orders
- Strong vitamin D & analogues sales with high margins, especially Calcifediol
- Halal certification in process at Veenendaal to access Asian markets
Capital Expenditure and Financing
Capital Expenditure:
- Q2 CapEx: $5.4 million
- H1 CapEx: $10.3 million
- Full-year guidance: Approximately INR 200 crores
- Includes maintenance CapEx and digital transformation initiatives (SAP implementation)
External Commercial Borrowing (ECB):
- CHF 200 million ECB in process
- First tranche of approximately $50 million expected before Christmas holidays or in Q4 FY27
- Upon completion, expected reduction in quarterly interest cost from INR 40 crore to INR 20-25 crore
- Currently completing final conditions precedents and tax opinions
Cash Position and Debt:
- Cash balance: Approximately INR 1,000 crores
- Net debt: Approximately $165 million at consolidated level
- Recent NCD raising at ~10% primarily for refinancing existing NCDs and maintenance CapEx
Guidance and Outlook
Revenue Outlook:
- FY27: No growth expected compared to FY26 revenue of INR 2,900 crores
- Medium-term (FY28-29): 10-12% annual growth expected
- Bavla facility: Expected revenue of INR 400-450 crores for full FY28
Margin Outlook:
- FY27 EBITDA margin: Approximately 15-16%
- Medium-term (FY28-29): EBITDA margin expected to exceed 20-21%
Operational Outlook:
- Expect recovery in second half FY27 for vitamin D analogs business
- Development pipeline increased from CHF 89 million to CHF 98 million
- 12+ late-phase projects including PPQ campaigns in portfolio
- Three commercial products added in current calendar year
- Increased orders from existing commercial products
Risk Factors and Challenges
- Business nature described as "lumpy" with dependency on molecule development timing
- Biotech funding constraints affecting early-phase development revenue
- Regulatory filing changes required for technology transfers take time
- Fixed cost structure makes EBITDA sensitive to revenue fluctuations
- Multi-jurisdictional complexities in ECB funding process